CORE E: NOVEL TARGET DISCOVERY AND ASSAY

新靶点发现和分析开发核心（NTDAC）将为加州大学洛杉矶分校、加州大学圣地亚哥分校、索尔克研究所和雪松西奈的研究人员提供咨询和一套其他国家资源无法提供的最先进的分子测量。新的NTDAC核心组装了一个全面和高度专业化的核心，具有生物质谱和蛋白质组学（Julian Whitelegge，主任）和ELISA检测开发（Pinchas Cohen，联席主任）的专业知识。这一生物医学核心的优势包括核心领导层在糖尿病研究方面的广泛专业知识、蛋白质和肽分析方面的广泛经验、生物信息学资源的可及性，以及NTDAC领导层与刚果民主共和国研究人员的合作，以协助刚果民主共和国研究人员进行战略规划和执行与刚果民主共和国使命相关的研究。核心目标包括：1)提供一个可访问的用户界面，以及时、经济、综合的方式满足每个DRC研究者的具体需求；2)提供发现质谱服务，提供适当的生物信息学，以实现敏感、准确的测量和质量控制；3)提供生物标志物鉴定、免疫捕获和自上而下的质谱鉴定，以确定铅蛋白和肽的生物功能。4)为新型多肽和蛋白质提供检测构建，优化临床可靠的检测方法；5)为新型检测方法提供ELISA服务，开发新的临床检测方法，为糖尿病患者提供更好的治疗效果。核心领导层的集体和互补专业知识非常出色，为刚果民主共和国的研究人员提供了探索和实施依赖于直接分析蛋白质和肽的实验策略的机会。新的NTDAC核心提供了发现蛋白质组学和肽组学，以及已引入MMPC（核心B）的脂质组学成分。核心将通过许多有利的相互作用与其他DRC核心协同作用，包括相互作用伙伴的识别（核心A），代谢和生理学研究的整合（核心B）以及与基因组学和遗传学核心相关的生物信息学资源的增强（c&d）。总的来说，我们研究胰岛素作用的蛋白质和肽，底物代谢和炎症信号的能力将推动UCSD-UCLA研究中心在发现肥胖和胰岛素抵抗病理生物学中涉及的关键生物分子方面取得进展，并为开发对抗糖尿病和糖尿病并发症的新治疗策略提供基础。

The Novel Target Discovery and Assay Development Core (NTDAC) will provide investigators at UCLA, UCSD, the Salk Institute and Cedars-Sinai with consultancy and a suite of state-of-the-art molecular measurements not available from other national resources. The new NTDAC core assembles a comprehensive and highly specialized core with expertize in biological mass spectrometry and proteomics (Julian Whitelegge, Director) and ELISA assay development (Pinchas Cohen, Co-Director). Strengths of this biomedical core include the extensive expertise ofthe core leadership in diabetes research, wide experience in protein and peptide analysis, access to bioinformatics resources, and the collegial outreach of NTDAC leadership to DRC investigators to assist in the strategic planning and execution of studies relevant to the DRC mission. Core goals include: 1) provide an accessible user interface toward meeting objectives in a timely, cost effective, and integrated manner individualized to the specific needs of each DRC investigator, 2) provide discovery mass spectrometry services with appropriate bioinformatics for sensitive, accurate measurements with quality control, 3) provide biomarker qualification, immunocapture and top-down mass spectrometry for qualification of lead proteins and peptides with respect to biological function, 4) provide assay construction for novel peptides and proteins, and optimization of reliable assays toward the clinic, 5) provide ELISA services for novel assays for development of new clinical assays for better patient outcomes in diabetes. The collective and complementary expertise of the core leadership is outstanding and provides DRC investigators with an opportunity to explore and implement experimental strategies that rely upon direct analysis of proteins and peptides. The new NTDAC core provides discovery proteomics and peptidomics, alongside the lipidomics component that has been introduced into the MMPC (core B). The core will synergize with the other DRC cores through many favorable interactions including identification of interaction partners (core A), integration with metabolism and physiology studies (core B) and enhanced bioinformatics resources related to the genomics and genetics cores (C & D). Collectively, our ability to study the proteins and peptides of insulin action, substrate metabolism, and inflammatory signaling will drive the UCSD-UCLA DRC forward in discovery of critical biological molecules involved in the pathobiology of obesity and insulin resistance, and provide a foundation for the development of novel therapeutic strategies to combat diabetes and diabetes complications.